Joost S.P. Vermaat

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo et al. · The Lancet Haematology · 2020 · 337 citations · Full text

Medicine, Hematology, Oncology +11

Mesenchymal Stem Cells Induce Resistance to Chemotherapy through the Release of Platinum-Induced Fatty Acids

Jeanine M.L. Roodhart, Laura G.M. Daenen, Edwin C.A. Stigter et al. · Cancer Cell · 2011 · 306 citations · Full text

Medicine, Cell Biology, Oncology +13

Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients

Laurens V. Beerepoot, Niven Mehra, Joost S.P. Vermaat et al. · Annals of Oncology · 2003 · 244 citations

Medicine, Cancer Biology, Oncology +15

Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer

Wigard P. Kloosterman, Marlous Hoogstraat, Oscar Paling et al. · Genome biology · 2011 · 208 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment

Joost S.P. Vermaat, Isaäc J. Nijman, Marco J. Koudijs et al. · Clinical Cancer Research · 2011 · 151 citations

Medicine, Genetics, Molecular Genetics +16